Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

EBS vs ANTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANTX Captures Overall Composite Edge (37.2 SELL vs 42.6 HOLD), While EBS Leads 4–2 on Growth & Valuation Pillars

ANTX Overall Winner 6-Pillar Tally: EBS 4 – 2 ANTX Matrix Metrics: EBS 6 – 4 ANTX

As of Nov 19, 2026, AN2 Therapeutics, Inc. (ANTX) captures the overall head-to-head institutional edge over Emergent Biosolutions, Inc. (EBS) on higher Unified Composite conviction (37.2/100 SELL vs. 42.6/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Options & Positioning), while EBS wins 4–2 across the 6-pillar growth and valuation breakdown. EBS trades at $5.15 (19.3x Forward P/E, 5.8% operating margin) versus ANTX at $5.22 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While EBS currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. ANTX 37.2/100 SELL), ANTX captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 5.8% operating margin) and revenue trajectory (+0.0% vs. -52.4% YoY).
  • Technical & Structure Timing Caution: EBS is currently in a Breakdown options structure phase (RSI 29.2); meanwhile ANTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EBS vs ANTX
EBS NYSE
Emergent Biosolutions, Inc.
Pharmaceutical Preparations
$5.15
-6.36% 1D
Market Cap $282.8M
TTM Revenue $649M
Forward P/E 19.3x
Beta / 30D Vol 0.90β · 54% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 51.0 Flow 67.0 Mom 59.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 29
RSI-14: 29.2 · SMA20: $6.14 · SMA50: $6.47
ANTX NASDAQ Head-to-Head Winner
AN2 Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$5.22
+5.45% 1D
Market Cap $190.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.75β · 98% Vol
Unified Composite Score
37.2 / 100 SELL
Tech 15.0 Fund 39.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 65
RSI-14: 65.0 · SMA20: $4.31 · SMA50: $4.52

6-Pillar Scorecard Institutional Category Breakdown (EBS 4 – 2 ANTX)

Columns: Metric · EBS · ANTX
1. Valuation Multiples EBS
Forward P/E 19.3x N/M
Trailing P/E 19.3x N/M
PEG Ratio 0.38x N/M
EV / Revenue 0.9x N/M
2. Growth & Scale ANTX
Revenue Growth (YoY) -52.4% +0.0%
Earnings Growth (YoY) -93.8% +0.0%
TTM Revenue (USD) $649M N/A
Market Cap $282.8M $190.1M
3. Profitability & Quality EBS
Gross Margin 43.4% N/A
Operating Margin 5.8% 0.0%
Net Profit Margin -40.2% 0.0%
Return on Equity (ROE) -58.2% -51.3%
4. Balance Sheet & Cash Flow EBS
Cash Generation (TTM) $188M -$30M
Cash Flow Margin 29.0% N/A
Net Cash / Leverage $332M Net Debt (1.62x D/E) $1.99 Book/Sh · -51.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANTX
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 84.5% (5th %ile) 134.2% (22nd %ile)
Put/Call OI Skew 2.48x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat EBS
OpEx & R&D Intensity 37.6% of Rev ($244M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EBS (6) vs ANTX (4)
Institutional Metric EBS ANTX Criterion Row Edge
Market Capitalization
Scale
$282.8M $190.1M Larger Scale EBS
Trailing P/E Ratio
Valuation
19.3x N/M Lower Multiple EBS
Forward P/E Ratio
Valuation
19.3x N/M Lower Multiple EBS
Revenue Growth (YoY)
Growth
-52.4% +0.0% Higher Growth ANTX
Operating Margin (TTM)
Profitability
5.8% 0.0% Higher Margin EBS
Net Profit Margin
Profitability
-40.2% 0.0% Higher Margin ANTX
Return on Equity (ROE)
Capital Efficiency
-58.2% -51.3% Higher ROE ANTX
52-Week Range Position
Momentum
8% ($4–$14) 68% ($1–$7) Stronger Trend ANTX
Beta / 30D Volatility
Risk Regime
0.90β · 54% Vol 0.75β · 98% Vol Lower Realized Risk EBS
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 37.2 / 100 (SELL) Higher Composite EBS
Trailing 12M Revenue (USD)
Operating Scale
$649M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
43.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.38x PEG · 0.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$188M ($332M Net Debt (1.62x D/E)) -$30M ($1.99 Book/Sh · -51.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANTX +61.94 pp
EBS: -16.94% · ANTX: +45.0%
3M Horizon EBS +11.53 pp
EBS: +1.38% · ANTX: -10.15%
6M Horizon ANTX +45.22 pp
EBS: -38.47% · ANTX: +6.75%
1Y Horizon ANTX +415.18 pp
EBS: -49.11% · ANTX: +366.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EBS vs ANTX. Trailing 12-month operating profitability (EBS 5.8% vs ANTX 0.0%) and valuation multiples (EBS 19.3x vs ANTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EBS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$649M
Gross Margin43.4%
Op. Margin5.8%
ROE / Fwd P/E-58.2% · 19.3x
ANTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-51.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EBS BREAKDOWN
33d in phase · OBV DISTRIBUTION
Current IV 84.5%
IV Percentile 5th %ile
Put/Call OI Skew 2.48x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact EBS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANTX CONSOLIDATION
177d in phase · OBV NEUTRAL
Current IV 134.2%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ANTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $5.81 · IV 78.8%

EBS Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($581)

Compare $581 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 78.8% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $6 / $7 Bull Call Spread

Buy 4x $6C · Sell 4x $7C · 32d

Net Entry $180 Debit
T+5d @ +5% Move +$21 (+12%)
Max Risk / Buffer $180 Capped
5d Edge & Liquidity 0.4x R:R · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $5P / $6-$7C Seagull

Sell 2x $5P · Buy 2x $6/$7C · 32d

Net Entry $60 Debit
T+5d @ +5% Move +$27 (+14.0% RoM)
Max Risk / Buffer -13.9% Put Cushion ($190 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EBS Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $282.8M market capitalization and 5.8% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($244M)
90D Engineering Disclosures 0 Published
ANTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $190.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EBS vs ANTX Key Questions & Quantitative Answers

As of Nov 19, 2026, AN2 Therapeutics, Inc. (ANTX) captures the overall head-to-head institutional edge over Emergent Biosolutions, Inc. (EBS) on higher Unified Composite conviction (37.2/100 SELL vs. 42.6/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Options & Positioning), while EBS wins 4–2 across the 6-pillar growth and valuation breakdown. EBS trades at $5.15 (19.3x Forward P/E, 5.8% operating margin) versus ANTX at $5.22 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EBS currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. ANTX 37.2/100 SELL), ANTX captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 5.8% operating margin) and revenue trajectory (+0.0% vs. -52.4% YoY). Technical & Structure Timing Caution: EBS is currently in a Breakdown options structure phase (RSI 29.2); meanwhile ANTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANTX leads the Growth & Scale pillar: EBS posts -52.4% YoY revenue growth and -93.8% YoY earnings growth on $649M TTM revenue (43.4% gross margin, 5.8% operating margin), compared with ANTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EBS generates $649M in USD-normalized revenue versus N/A for ANTX. In operating R&D and SG&A reinvestment, EBS deploys 37.6% of Rev ($244M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANTX.

EBS screens cheaper on headline valuation multiples. EBS trades at 19.3x Forward P/E, 19.3x Trailing P/E, 0.38x PEG, and 0.9x EV/Revenue (29.0% FCF margin), whereas ANTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EBS (-58.2% ROE) versus ANTX (-51.3% ROE) capital efficiency.

In options market volatility and institutional positioning, EBS carries 84.5% implied volatility (5th %ile, Compressed (<25th %ile)), a 2.48x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.90β · 54% Vol realized risk). By comparison, ANTX carries 134.2% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.